



NMS Labs

CONFIDENTIAL

200 Welsh Road, Horsham, PA 19044-2208
Phone: (215) 657-4900 Fax: (215) 657-2972
e-mail: nms@nmslabs.com

Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

Demo Report

Report Issued 03/30/2020 13:01
Last Report Issued 09/18/2018 09:04

88888
Clinical Example Report
Attn: Example Reports
200 Welsh Road
Horsham, PA 19044

Patient Name 3226B
Patient ID 3226B
Chain 18001346
Age Not Given **DOB** Not Given
Gender Not Given
Workorder 18001346
Received 09/18/2018 07:20

Sample ID 18001346-001
Matrix Blood
Patient Name 3226B
Patient ID 3226B
Container Type Clear vial

Collect Dt/Tm Not Given
Source Not Given

Approx Vol/Weight Not Given

Receipt Notes Not frozen as required

Analysis and Comments	Result	Units	Reporting Limit	Notes
3226B Olanzapine and Metabolite, Blood				
Analysis by High Performance Liquid Chromatography/ Tandem Mass Spectrometry (LC-MS/MS)				
N-desmethyloanzapine Synonym(s): Olanzapine Metabolite Schizophrenic patients stabilized with olanzapine at an average daily dose of 14 mg had steady-state desmethyloanzapine plasma concentrations averaging 6.9 +/- 4.7 ng/mL. The blood to plasma ratio is not known for this compound.	None Detected	ng/mL	1.0	
Olanzapine Synonym(s): Zyprexa® Recommended antipsychotic range in adults: 20-80 ng/mL plasma. The blood to plasma ratio of olanzapine is approximately 0.6.	None Detected	ng/mL	3.0	

This test was developed and its performance characteristics determined by NMS Labs. It has not been cleared or approved by the US Food and Drug Administration.